BioXcel Therapeutics' Approved Drug For Bipolar Disorders/Schizophrenia Shows No Evidence Of Worsening Or Withdrawal In Post-Marketing Study
Portfolio Pulse from Vandana Singh
BioXcel Therapeutics Inc (NASDAQ:BTAI) announced positive topline results from a post-marketing study of Igalmi (dexmedetomidine) sublingual film, showing no evidence of tachyphylaxis, tolerance, or withdrawal. The study involved 28 inpatient adults with bipolar disorders or schizophrenia and demonstrated improvement in agitation symptoms with favorable safety results.
June 25, 2024 | 6:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioXcel Therapeutics' post-marketing study of Igalmi showed no evidence of worsening or withdrawal, with favorable safety results and improvement in agitation symptoms. Shares are up 2.10%.
The positive results from the post-marketing study of Igalmi, showing no evidence of worsening or withdrawal and favorable safety results, are likely to boost investor confidence in BioXcel Therapeutics. This is reflected in the 2.10% increase in share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100